Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer

CHI-SHIN TSENGYang, Jui-HanJui-HanYangSHI-WEI HUANGWang, Yu-JenYu-JenWangCHUNG-HSIN CHENYEONG-SHIAU PUCHIA-HSIEN CHENGCHAO-YUAN HUANG2023-06-272023-06-272023-06-201471-2407https://scholars.lib.ntu.edu.tw/handle/123456789/633106To investigate the survival outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line novel androgen receptor axis-targeted therapies (ARATs) and prognostic factors for patient survival.enAbiraterone acetate; Androgens; Castration; Enzalutamide; Prostatic neoplasms[SDGs]SDG1[SDGs]SDG3Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancerjournal article10.1186/s12885-023-10885-437340337